PURPOSE: Translocator protein (TSPO) concentrations are elevated in glioma, suggesting a role for TSPO positron emission tomography (PET) imaging in this setting. In preclinical PET studies, we evaluated a novel, high-affinity TSPO PET ligand, [(18)F]VUIIS1008, in healthy mice and glioma-bearing rats. PROCEDURES: Dynamic PET data were acquired simultaneously with [(18)F]VUIIS1008 injection, with binding reversibility and specificity evaluated in vivo by non-radioactive ligand displacement or blocking. Compartmental analysis of PET data was performed using metabolite-corrected arterial input functions. Imaging was validated with histology and immunohistochemistry. RESULTS: [(18)F]VUIIS1008 exhibited rapid uptake in TSPO-rich organs. PET ligand uptake was displaceable with non-radioactive VUIIS1008 or PBR06 in mice. Tumor accumulation of [(18)F]VUIIS1008 was blocked by pretreatment with VUIIS1008 in rats. [(18)F]VUIIS1008 exhibited improved tumor-to-background ratio and higher binding potential in tumors compared to a structurally similar pyrazolopyrimidine TSPO ligand, [(18)F]DPA-714. CONCLUSIONS: The PET ligand [(18)F]VUIIS1008 exhibits promising characteristics as a tracer for imaging glioma. Further translational studies appear warranted.
PURPOSE:Translocator protein (TSPO) concentrations are elevated in glioma, suggesting a role for TSPO positron emission tomography (PET) imaging in this setting. In preclinical PET studies, we evaluated a novel, high-affinity TSPO PET ligand, [(18)F]VUIIS1008, in healthy mice and glioma-bearing rats. PROCEDURES: Dynamic PET data were acquired simultaneously with [(18)F]VUIIS1008 injection, with binding reversibility and specificity evaluated in vivo by non-radioactive ligand displacement or blocking. Compartmental analysis of PET data was performed using metabolite-corrected arterial input functions. Imaging was validated with histology and immunohistochemistry. RESULTS: [(18)F]VUIIS1008 exhibited rapid uptake in TSPO-rich organs. PET ligand uptake was displaceable with non-radioactive VUIIS1008 or PBR06 in mice. Tumor accumulation of [(18)F]VUIIS1008 was blocked by pretreatment with VUIIS1008 in rats. [(18)F]VUIIS1008 exhibited improved tumor-to-background ratio and higher binding potential in tumors compared to a structurally similar pyrazolopyrimidineTSPO ligand, [(18)F]DPA-714. CONCLUSIONS: The PET ligand [(18)F]VUIIS1008 exhibits promising characteristics as a tracer for imaging glioma. Further translational studies appear warranted.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Paul Edison; Hilary A Archer; Alexander Gerhard; Rainer Hinz; Nicola Pavese; Federico E Turkheimer; Alexander Hammers; Yen Fong Tai; Nick Fox; Angus Kennedy; Martin Rossor; David J Brooks Journal: Neurobiol Dis Date: 2008-08-15 Impact factor: 5.996
Authors: Kerstin Maaser; Patricia Grabowski; Andreas P Sutter; Michael Höpfner; Hans-Dieter Foss; Harald Stein; Gerd Berger; Moshe Gavish; Martin Zeitz; Hans Scherübl Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent Journal: Lancet Neurol Date: 2010-08-10 Impact factor: 44.182
Authors: Dewei Tang; Matthew R Hight; Eliot T McKinley; Allie Fu; Jason R Buck; R Adam Smith; Mohammed Noor Tantawy; Todd E Peterson; Daniel C Colvin; M Sib Ansari; Michael Nickels; H Charles Manning Journal: J Nucl Med Date: 2012-01-17 Impact factor: 10.057
Authors: Yota Fujimura; Yasuyuki Kimura; Fabrice G Siméon; Leah P Dickstein; Victor W Pike; Robert B Innis; Masahiro Fujita Journal: J Nucl Med Date: 2009-12-15 Impact factor: 10.057
Authors: Hervé Boutin; Christian Prenant; Renaud Maroy; James Galea; Andrew D Greenhalgh; Alison Smigova; Christopher Cawthorne; Peter Julyan; Shane M Wilkinson; Samuel D Banister; Gavin Brown; Karl Herholz; Michael Kassiou; Nancy J Rothwell Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240
Authors: Dewei Tang; Jun Li; Jason R Buck; Mohamed Noor Tantawy; Yan Xia; Joel M Harp; Michael L Nickels; Jens Meiler; H Charles Manning Journal: Mol Imaging Biol Date: 2017-08 Impact factor: 3.488
Authors: Mohammed N Tantawy; H Charles Manning; Todd E Peterson; Daniel C Colvin; John C Gore; Wenfu Lu; Zhenbang Chen; C Chad Quarles Journal: Mol Imaging Biol Date: 2018-04 Impact factor: 3.488
Authors: Nathalie L Albert; M Unterrainer; D F Fleischmann; S Lindner; F Vettermann; A Brunegraf; L Vomacka; M Brendel; V Wenter; C Wetzel; R Rupprecht; J-C Tonn; C Belka; P Bartenstein; M Niyazi Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-19 Impact factor: 9.236
Authors: Yan Xia; Kaitlyn Ledwitch; Georg Kuenze; Amanda Duran; Jun Li; Charles R Sanders; Charles Manning; Jens Meiler Journal: J Biomol NMR Date: 2019-06-26 Impact factor: 2.835
Authors: Allison S Cohen; Jun Li; Matthew R Hight; Eliot McKinley; Allie Fu; Adria Payne; Yang Liu; Dawei Zhang; Qing Xie; Mingfeng Bai; Gregory D Ayers; Mohammed Noor Tantawy; Jarrod A Smith; Frank Revetta; M Kay Washington; Chanjuan Shi; Nipun Merchant; H Charles Manning Journal: Clin Cancer Res Date: 2020-09-15 Impact factor: 12.531
Authors: Yiu-Yin Cheung; Michael L Nickels; Dewei Tang; Jason R Buck; H Charles Manning Journal: Bioorg Med Chem Lett Date: 2014-08-08 Impact factor: 2.823
Authors: Marcus Unterrainer; D F Fleischmann; C Diekmann; L Vomacka; S Lindner; F Vettermann; M Brendel; V Wenter; B Ertl-Wagner; J Herms; C Wetzel; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-22 Impact factor: 9.236
Authors: Dewei Tang; Jun Li; Michael L Nickels; Gang Huang; Allison S Cohen; H Charles Manning Journal: Mol Imaging Biol Date: 2019-02 Impact factor: 3.488